OBR Daily Commentary

forumImage

Roche's Tecentriq Gets 2 EU Approvals To Treat Adults With NSCLC, ES-SCLC

(RTTNews) Sept 6, 2019 - Swiss drug major Roche Group announced Friday two approvals from European Commission for Tecentriq (atezolizumab) to treat adults with non-squamous non-small cell lung cancer or NSCLC, the most common form of advanced lung cancer, and extensive-stage small cell lung cancer or ES-SCLC, respectively. In a statement, the company announced that the European Commission or EU has approved and granted marketing authorisation for Tecentriq in combination with chemotherapy (carboplatin and Abraxane), for the initial treatment of adults with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.

Read Article arrow

H. Jack West, MD (Posted: September 06, 2019)

quotes

The approval of the IMpower133 regimen (carbo/etoposide/atezolizumab) should represent a new standard of care for first line extensive stage SCLC in Europe, though the results of the CASPIAN trial (cisplatin or carboplatin with etoposide, +/- durvalumab) that are being presented at the World Conference on Lung Cancer in Barcelona in a few days will likely be an alternative if approved.

The IMpower130 regimen of carbo/nab-paclitaxel/atezolizumab for non-squamous NSCLC won't displace the KEYNOTE-189 regimen (cis or carbo + pemetrexed + pembrolizumab), but it's an alternative that will be of some use for patients who aren't candidates for pemetrexed due to poor renal function, severe rash with pemetrexed, or some other uncommon situations.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...